New: our own Hairmetry line. Every ingredient explained

Topic

Minoxidil forms compared

Solution, foam, oral tablets, sublingual and extended-release minoxidil deliver the same drug in different ways; this page compares them.

hair lossthinningreceding hairlinesheddingbrows lashes beard

Key takeaways

  • Topical 5% is the proven, cheap default for men and women. In men 5% beat 2% in 393 men (Olsen 2002); in women a Cochrane review found no 2% versus 5% difference (van Zuuren 2016).
  • Foam versus solution: foam is propylene-glycol-free, so it causes less itch and flaking. Once-daily 5% foam matched twice-daily 2% solution in 322 women (+23.9 versus +24.2 hairs/cm2), though the non-inferiority margin was narrowly missed (Blume-Peytavi 2016).
  • Higher strengths do not help: 10% was no better than 5% and more irritating in 90 men (Ghonemy 2021).
  • Oral is not clearly better. Every direct trial found no significant density difference, including 90 men (Penha 2024), and a 2025 meta-analysis of four RCTs (279 people) found about double the hypertrichosis risk on oral (Sobral 2025).
  • Dose: in 100 men, 2.5 mg matched 5 mg over 24 weeks with fewer side effects (Carvalho 2025).
  • Sublingual 5 mg matched oral 5 mg in 110 men, with fewer palpitations (0% versus 9.3%) (Sanabria 2025); a phase 3 finished in May 2026 with no results posted.
  • Extended-release oral (VDPHL01) was reported by its company to give +30 to +33 versus +7 hairs/cm2 at 6 months in men; it is not peer reviewed (trial record).
  • Compounded capsules carry dosing-error risk: twelve severe reactions among about 1,700 prescriptions, one stroke after 1,000 mg instead of 1 mg (Moreno-Arrones 2022).
  • Stopping reverses the benefit for every form (Price 1999).

The science

Form Strength / dose Access Evidence Best for Main downsides
Solution 2%, 5% twice daily Over the counter in the US and UK, mostly in the EU Several large RCTs and meta-analyses First line, lowest cost Alcohol and propylene glycol itch, greasy styling, facial hair in women
Foam 5% twice daily (men), once daily (women) Over the counter (US, UK) RCT in 352 men; women's trials Sensitive or itchy scalps, styling Flammable; same absorption warnings; somewhat dearer
Oral tablet, low dose 1.25 to 5 mg/day (common ranges) Prescription, off-label for hair Small RCTs equal to topical; a 1,404-patient safety cohort (Vañó-Galván 2021) People who skip topicals, scalp inflammation, plateau Extra body hair, ankle swelling, dizziness; contraindicated in pregnancy
Compounded capsule any Common outside the US Same drug; no separate trials Only where tablets are unavailable Dosing errors
Sublingual 0.45 to 5 mg Investigational Phase 1b and a 110-man RCT Possibly fewer palpitations Evidence mostly from one group with patents
Extended-release oral 4.5 to 8.5 mg Investigational Company press release Once-daily steady dosing Unpublished

Choosing by profile

  • Men, crown thinning: topical 5% foam or solution; add finasteride for more. The combination improved 94.1% of 450 men versus 80.5% on finasteride and 59% on minoxidil (Hu 2015).
  • Women: 5% foam once daily or 2% solution twice daily; facial hair is the main limit. Women develop hypertrichosis on oral minoxidil at lower doses than men, and pregnancy and breastfeeding rule it out.
  • Hairline and temples: minoxidil can thicken miniaturised hairs but cannot regrow follicles that are gone; the US men's label covers the vertex only (label).
  • Curly, coily, thick or dry hair: solutions can leave residue and itch; foam or a lightweight vehicle may suit. No hair-type-specific trials were found.
  • Scalp irritation or dandruff: patch testing usually implicates propylene glycol rather than minoxidil, so propylene-glycol-free foam is the usual switch.
  • Cat owners: topical minoxidil is toxic to cats; 8 of 62 symptomatic cats died in a poison-centre series (Tater 2021).

What it means by hair profile

See "Choosing by profile". Scalp type, curl pattern and porosity were not stratified in the trials found.

Myths and facts

  • Myth: oral minoxidil is far stronger than topical. Fact: direct trials show similar density gains.
  • Myth: more minoxidil, faster results. Fact: the US labels say using more will not improve results (label).
  • Myth: the initial shed means it is not working. Fact: temporary shedding in the first weeks is common.
  • Myth: a SULT1A1 test or booster guarantees results. Fact: the evidence comes mostly from the company that sells them, and tretinoin adds irritation without proven benefit.

Practical recommendations

  • Give any form 4 to 6 months before judging it: the men's label says 2 to 4 months for first results, and the women's foam label says some women need at least 6 months (label).
  • Use it consistently. Weighing oral minoxidil is a decision for a prescriber: it is off-label, and a 2025 consensus lists contraindications (past pericardial effusion, heart failure, pregnancy) and recommends low starting doses (Akiska 2025).

Bottom line

Start with topical 5% (foam if your scalp itches). Oral, sublingual and extended-release forms mainly offer convenience, not stronger regrowth, and add heart-rate, swelling and body-hair trade-offs. Discuss with a doctor before using oral minoxidil. See minoxidil for the full evidence.

Studies 19

Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002

Design
rct
People
393
Duration
48 weeks
Who
men with androgenetic alopecia

Tested: 5% vs 2% topical minoxidil solution vs placebo, twice daily

Result: 5% was superior to 2% and placebo, with about 45% more regrowth than 2% at week 48 and faster onset; itch and irritation were more common with 5%.

Read the study ↗

van Zuuren EJ et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016

Design
systematic review
People
5,290
Who
women with female pattern hair loss (47 trials)

Tested: topical minoxidil and other treatments vs placebo

Result: Minoxidil gave about 13.2 more hairs/cm2 than placebo; there was no difference between 2% and 5% in women.

Read the study ↗

Blume-Peytavi U et al. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a phase III study. 2016

Design
rct
People
322
Duration
24 weeks
Who
women with female pattern hair loss

Tested: 5% foam once daily vs 2% solution twice daily

Result: Gains were +23.9 vs +24.2 hairs/cm2; the prespecified non-inferiority margin was narrowly missed.

Read the study ↗

Ghonemy S et al. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in male androgenetic alopecia. 2021

Design
rct
People
90
Duration
36 weeks
Who
men with androgenetic alopecia

Tested: 10% vs 5% topical minoxidil vs placebo

Result: 10% was not better than 5% and was more irritating.

Read the study ↗

Penha MA et al. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024

Design
rct
People
90
Duration
24 weeks
Who
men with androgenetic alopecia

Tested: oral minoxidil 5 mg vs topical 5% twice daily, double-dummy

Result: No significant difference in terminal hair density; oral looked better only on vertex photographs; hypertrichosis affected 49% on oral.

Read the study ↗

Asilian A et al. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in androgenetic alopecia: a randomized controlled trial. 2024

Design
rct
People
65
Duration
6 months
Who
men and women with androgenetic alopecia

Tested: oral minoxidil 1 mg vs topical 5%

Result: No significant difference between oral and topical; topical was numerically better.

Read the study ↗
Show 13 more studies

Vahabi-Amlashi S et al. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss. 2021

Design
rct
People
72
Duration
9 months
Who
women with female pattern hair loss

Tested: oral minoxidil 0.25 mg vs topical 2%

Result: Both improved (oral from 102 to 115 hairs/cm2) with no difference between groups.

Read the study ↗

Sobral et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. 2025

Design
meta analysis
People
279
Who
people with androgenetic alopecia (4 RCTs)

Tested: oral vs topical minoxidil

Result: Hair density did not differ (standardised difference 0.02); oral roughly doubled the risk of hypertrichosis (relative risk 2.01).

Read the study ↗

Carvalho et al. Oral minoxidil 2.5 mg versus 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. 2025

Design
rct
People
100
Duration
24 weeks
Who
men with androgenetic alopecia

Tested: oral minoxidil 2.5 mg vs 5 mg

Result: No difference in non-vellus hair density (0.9 hairs/cm2); ankle swelling and dizziness were more common on 5 mg.

Read the study ↗

Sanabria B et al. Sublingual minoxidil 5 mg versus oral minoxidil 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. 2025

Design
rct
People
110
Who
men with androgenetic alopecia

Tested: sublingual vs oral minoxidil 5 mg

Result: Same efficacy (total density +24.5 vs +21.8 per cm2) with fewer palpitations on sublingual (0% vs 9.3%).

Read the study ↗

ClinicalTrials.gov NCT06724614. Extended-release oral minoxidil (VDPHL01) in men with pattern hair loss, phase 2/3. Veradermics

Design
rct
Duration
6 months
Who
men with male pattern hair loss

Tested: extended-release oral minoxidil vs placebo

Result: The company reported +30.3 and +33.0 vs +7.3 non-vellus hairs/cm2 at 6 months in a press release in April 2026; no peer-reviewed paper yet.

Read the study ↗

Moreno-Arrones OM et al. Serious adverse effects from compounding errors with low-dose oral minoxidil for alopecia treatment. 2022

Design
case series
Who
patients given compounded oral minoxidil capsules

Tested: compounded low-dose oral minoxidil

Result: Twelve severe reactions (0.7% of about 1,700 prescriptions) came from capsules holding 10 to 100 times the prescribed dose.

Read the study ↗

Hu R et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized comparative study in Chinese patients. 2015

Design
rct
People
450
Duration
12 months
Who
Chinese men with androgenetic alopecia

Tested: finasteride vs 5% minoxidil vs both

Result: Improved: 80.5% on finasteride, 59% on minoxidil, 94.1% on the combination.

Read the study ↗

Tater KC et al. Topical minoxidil exposures and toxicoses in dogs and cats: 211 cases (2001-2019). J Am Anim Hosp Assoc. 2021

Design
case series
People
211
Who
dogs and cats reported to a poison centre

Tested: accidental exposure to topical minoxidil

Result: Signs followed even a few drops or licks; 8 of 62 symptomatic cats died.

Read the study ↗

Vano-Galvan S et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. 2021

Design
cohort
People
1,404
Who
people taking low-dose oral minoxidil for hair loss

Tested: low-dose oral minoxidil

Result: Hypertrichosis 15.1%, lightheadedness 1.7%, fluid retention 1.3%, fast heartbeat 0.9%; 1.7% stopped for side effects and no life-threatening events occurred.

Read the study ↗

Akiska YM et al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement. JAMA Dermatol. 2025

Design
review
Who
43 hair specialists from 12 countries

Tested: low-dose oral minoxidil practice

Result: Common starting doses were 1.25 mg/day in adult women and 2.5 mg/day in adult men; pregnancy, past pericardial effusion and heart failure were contraindications.

Read the study ↗

Price VH et al. Changes in hair weight and hair count in men with androgenetic alopecia after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999

Design
rct
People
36
Duration
96 weeks on treatment, then 24 weeks off
Who
men with androgenetic alopecia

Tested: 5% or 2% topical minoxidil vs placebo vs no treatment

Result: About 30% hair-weight gain was maintained while treated and was lost within 24 weeks of stopping.

Read the study ↗

Minoxidil 5% topical foam for women, over-the-counter drug facts. DailyMed

Design
label
Who
women with thinning hair

Tested: 5% minoxidil foam, half a capful once daily

Result: Results may appear at 3 months and some women need at least 6 months; hair loss begins again if use stops; the foam is extremely flammable and may be harmful in pregnancy or breastfeeding.

Read the study ↗

Minoxidil 5% topical foam for men, over-the-counter drug facts. DailyMed

Design
label
Who
men with thinning hair

Tested: 5% minoxidil foam, half a capful twice daily

Result: Labelled for regrowth on the top of the scalp (vertex) only, not for a receding hairline; using more or more often will not improve results.

Read the study ↗